Current Oncology, Volume 31, Issue 2
2024 February - 40 articles
Cover Story: Claudins, components of tight cell junctions in epithelial and endothelial cells, have emerged as potential therapeutic targets in oncology. Claudin 18.2 has gained traction in gastroesophageal adenocarcinoma (GAC). In a recent phase III trial, zolbetuximab, an anti-claudin 18.2 monoclonal antibody, has been studied in combination with front-line therapies platinum and fluoropyrimidine therapies in advanced GAC. Patients in both studies were HER-2-negative and claudin-positive (≥75% of tumor cells showed moderate to strong membranous CLDN18 staining). The survival outcomes were improved with the addition of zolbetuximab. Here, we discuss the current potential of zolbetuximab in advanced GAC along with questions that still remain. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.